Google
REGN Stock Price & Analysis — Regeneron Pharmaceuticals Inc (Healthcare >> Biotechnology)
REGN FAQ
What is REGN's P/E ratio?
Regeneron Pharmaceuticals Inc (REGN) currently trades at a P/E ratio of 18.14.
What is REGN's ROE?
Regeneron Pharmaceuticals Inc reports a Return on Equity (ROE) of 1,000,000.00%.
What is REGN's dividend yield?
Regeneron Pharmaceuticals Inc offers a dividend yield of 0.49%.
What is REGN's Quality Score?
Our AI rates REGN's overall financial quality at 92 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy REGN?
Our AI Timing Score for REGN is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does REGN belong to?
Regeneron Pharmaceuticals Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
REGN AI Analysis Summary
Our AI summary for REGN: Regeneron Pharmaceuticals Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 18.14, ROE of 1,000,000.00%, a dividend yield of 0.49%. Its financial Quality Score stands at 92/100 — fundamentals stronger than most of the market. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 759.24
Price
-3.39
(-0.44%)
Day Change
|
|
|---|
REGN, the overall quality is excellent ( Quality = 92) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are ok , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
64% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 81 |
| Magic Formula Rank by ROA |
707
|
| Magic Formula Rank by ROE |
707
|
| Magic Formula Rank by ROIC |
805
|
| Price | 759.24 |
| PBV / Sector |
1,000,000.00 / 44,219.29
GREAT
|
| Earning Per Share | 41.86 |
| PE / Sector |
18.14 / 19.28
|
| PEG or PE/Growth / Sector |
5.78 / 1.23
|
| Average 1M Daily Value |
530.04 M
|
| Average 1W Daily Value |
769.32 M
|
| Timing Factors |
|
85% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
68% |
| Return to Investors |
|
41% |
| Registration Details |
| Analyze Date | 2026-08-04 08:02:04 |
| Symbol | REGN |
| Name | REGENERON PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 101.14 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 78,516.57 / 9,645.64 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
Phone: 914 847 7000
Website: https://www.regeneron.com
Employees: 15,410
Sector: Healthcare >> Biotechnology
Description: Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap